Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Et fase 2-effektivitets- og sikkerhedsstudie af GAL-101, 2 % oftalmisk opløsning i ikke-foveal geografisk atrofi sekundært til ikke-neovaskulær AMD (eDREAM)

9. november 2026 opdateret af: Galimedix Therapeutics Inc

En fase 2, dobbeltmaskeret, randomiseret, multicenter, parallel gruppe, placebokontrolleret undersøgelse for at undersøge effektiviteten og sikkerheden af ​​GAL-101, 2 %, oftalmisk opløsning hos patienter med ikke-foveal geografisk atrofi sekundært til ikke-neovaskulær alder- relateret makuladegeneration: EDREAM-undersøgelse

Age-related macular degeneration (AMD) affects millions of elderly patients. When advanced, there is Geographic Atrophy (GA) in the retina. This means that there is an area with a loss of light-sensitive cells, called photoreceptors. That part of the retina can no longer see. Atrophy begins as a small spot in the retina distant from the fovea which is the part of the retina responsible for sharp central vision. The GA grows, and when it reaches the fovea, vision is severely diminished, and details cannot be seen anymore. The purpose of the eDREAM study is to understand if GAL-101 can slow the growth of GA and prevent it from reaching the fovea. GAL-101 is given as eyedrops. eDREAM patients will administer study eyedrops every day. Patients will be assigned by chance (randomly) to receive either eye-drops that contain the new medication, GAL-101, or eyedrops without the active drug (Placebo). Neither patients nor doctors will know which treatment was assigned to each patient until the end of the study.

Studieoversigt

Status

Rekruttering

Intervention / Behandling

Detaljeret beskrivelse

In this study, if both eyes qualify for the study, the eye with the better BCVA will be defined as the study eye. If both eyes qualify for the study and have identical BCVA, then the eye with higher baseline peripheral retinal degenerations (PRD) will be defined as the study eye. If baseline PRD is identical, then the right eye (OD) will be defined as the study eye. Only the study eye will be dosed with the Investigation Medicinal Product (IMP).

During visits, patients will administer 3 applications of 1 drop of GAL-101 or a matching Placebo that does not contain the active pharmaceutical ingredient (API) at 5-minute intervals (i.e., 1st application, wait 5 minutes, 2nd application, wait 5 minutes, 3rd application), under the supervision of trained and authorized study personnel. In between visits, patients will be instructed to administer 2 applications of 1 drop at 5-minute intervals once a day.

The study will be comprised of a 12- to 24-month treatment period determined individually according to patients' overall placement in global study randomization. All patients will participate at least 12 months of treatment. The visit schedule includes the following: Screening visits (Visit 1a and 1b) for image capture and confirmation of study eligibility by a reading center; Baseline/Randomization/Day 1 (Visit 2); a phone call at 2 weeks; and on-treatment clinic visits for safety and efficacy evaluations at 1 month, 3 months, 6 months, 9 months, and 12 months. Patients will continue to attend on-treatment clinic visits at 3-month intervals after 12 months until the last patient randomized in the study has completed 12 months of study treatment.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

110

Fase

  • Fase 2

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

  • Navn: Galimedix Inc. c/o Imperial CRS, MD
  • Telefonnummer: +1 (301) 9179191
  • E-mail: info@galimedix.com

Undersøgelse Kontakt Backup

Studiesteder

      • Yerevan, Armenien, 0048
        • Rekruttering
        • Ophthalmological Center After S.V. Malayan
        • Kontakt:
        • Ledende efterforsker:
          • Lilit Voskanyan, MD, PhD
    • California
      • Beverly Hills, California, Forenede Stater, 90211
        • Rekruttering
        • Retina-Vitreous Associates Medical Group
        • Ledende efterforsker:
          • David Boyer, MD
        • Kontakt:
      • Walnut Creek, California, Forenede Stater, 94598
        • Rekruttering
        • Bay Area Retina Associates
        • Ledende efterforsker:
          • Roger Goldberg, MD
        • Kontakt:
    • Maryland
      • Hagerstown, Maryland, Forenede Stater, 21740
        • Suspenderet
        • Cumberland Valley Retina Consultants
      • Bordeaux, Frankrig, 33000
        • Rekruttering
        • Centre Rétine Gallien
        • Kontakt:
        • Ledende efterforsker:
          • Eric Fourmaux, MD
      • Lyon, Frankrig, 69317
        • Rekruttering
        • Hopital de La Croix-Rousse Service D'Ophtalmologie Groupement Hospitalier Nord Hospices Civils de Lyon
        • Kontakt:
        • Ledende efterforsker:
          • Laurent KODJIKIAN, MD
      • Marseille, Frankrig, 13008
        • Rekruttering
        • Centre Monticelli Paradis d'Ophtalmologie
        • Kontakt:
        • Ledende efterforsker:
          • François Devin, MD
      • Paris, Frankrig, 75006
        • Rekruttering
        • Centre Ophtalmologique Odéon
        • Kontakt:
        • Kontakt:
          • Favard, MD
        • Ledende efterforsker:
          • Catherine Favard, MD
      • Tours, Frankrig, 37540
        • Rekruttering
        • Centre médico-chirurgical de Touraine
        • Kontakt:
        • Ledende efterforsker:
          • Sam Razavi, MD
      • Tbilisi, Georgien, 0162
        • Rekruttering
        • Akhali Mzera Limited
        • Kontakt:
        • Ledende efterforsker:
          • Shalva Skhirtladze, MD
      • Tbilisi, Georgien, 0186
        • Rekruttering
        • Caucasus Medical Centre LLC
        • Kontakt:
        • Ledende efterforsker:
          • Mikheil Omiadze, MD, PhD
      • Kildare, Irland, W91 W535
        • Rekruttering
        • UPMC Kildare Hospital Prosperous Rd Clane, Kildare Ireland
        • Ledende efterforsker:
          • Eugene Ng, MD
        • Kontakt:
      • Waterford, Irland, X91 DH9W
        • Rekruttering
        • Institute of Eye Surgery (IOES Waterford)
        • Ledende efterforsker:
          • Eugene Ng, MD
        • Kontakt:
      • Jerusalem, Israel, 9112001
        • Rekruttering
        • Hadassah Medical Center
        • Kontakt:
        • Ledende efterforsker:
          • Tareq Jaouni, MD
      • Tel Aviv, Israel, 6423906
        • Rekruttering
        • Tel Aviv Medical Center
        • Kontakt:
        • Ledende efterforsker:
          • Omer Trivizki, MD
    • Milano
      • Milan, Milano, Italien, 20123
        • Rekruttering
        • Medical Retina & Imaging Unit, IRCCS MultiMedica, Ospedale San Giuseppe
        • Kontakt:
        • Ledende efterforsker:
          • Stela Vujosevic, MD
      • Milan, Milano, Italien, 20132
        • Rekruttering
        • Unità di Oculistica, IRCCS Ospedale San Raffaele
        • Kontakt:
        • Ledende efterforsker:
          • Francesco Bandello, MD
    • Roma
      • Roma, Roma, Italien, 00184
        • Rekruttering
        • UOS Retina Medica, P.O. Britannico, IRCCS Fondazione G.B. Bietti per lo Studio e la Ricerca in Oftalmologia
        • Kontakt:
        • Ledende efterforsker:
          • Mariacristina Parravanno, MD
      • Bonn, Tyskland, 53127
        • Rekruttering
        • Universitäts-Augenklinik Bonn
        • Ledende efterforsker:
          • Kristina Pfau, MD
        • Kontakt:
      • Freiburg im Breisgau, Tyskland, 79106
        • Rekruttering
        • Universitätsklinikum Freiburg Klinik für Augenheilkunde
        • Ledende efterforsker:
          • Hansjuergen Agostini, MD
        • Kontakt:
      • Hanover, Tyskland, 30625
      • Neubrandenburg, Tyskland, 17036
        • Rekruttering
        • Dietrich Bonhoeffer Klinikum
        • Kontakt:
        • Ledende efterforsker:
          • Christian Brinkmann, MD
      • Tübingen, Tyskland, 72076
        • Rekruttering
        • Universitätsklinikum Tübingen, Department für Augenheilkunde.
        • Kontakt:
        • Ledende efterforsker:
          • Felix Reichel, MD
      • Ulm, Tyskland, 89075
        • Ikke rekrutterer endnu
        • UNIVERSITÄTSKLINIKUM ULM Klinik für Augenheilkunde
        • Kontakt:
        • Ledende efterforsker:
          • Armin Wolf, MD

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

55 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • ≥55 years of age

  • Willing and able to provide written informed consent

  • Willing and able to comply with the study schedule and study assessments

  • Able to successfully administer ophthalmic solution or have an appropriate designee (e.g., family member, health care professional) who can administer ophthalmic solution

  • BCVA of ≥50 letters in the study eye using Early Treatment Diabetic Retinopathy Study (ETDRS) chart (i.e., 20/100 Snellen equivalent). Criterion will be confirmed at Baseline

  • Refractive error between +3 and -6 diopters spherical equivalent in the study eye

  • Sufficiently clear ocular media and adequate pupillary dilation to permit quality fundus imaging of the study eye, in the opinion of the Investigator. Criterion will be confirmed at Baseline

  • Diagnosed with non-foveal GA secondary to non-neovascular AMD in the study eye, as confirmed by the reading center

    1. Well-delineated cumulative GA area between 1.25 and 12.0 mm2
    2. If GA is multifocal, at least 1 lesion ≥1.25 mm2
    3. GA lesions must be located outside a ≥100 µm radius from the center point of the fovea (i.e., this area must have intact retinal pigment epithelium [RPE] and outer retina)
    4. GA lesions must be located (partially or wholly) within a 2000 µm radius from the center point of the fovea
    5. GA lesions must be completely located within FAF imaging field (field 2 to 30-degree image centered on the fovea). GA lesion borders must be >300 µm from image edges
    6. GA lesions must be >300 µm from the optic disc and/or peripapillary atrophy
    7. Area of PRD must be cumulatively between 7.25 and 25.0 mm2

Exclusion Criteria:

  1. Presence or history of choroidal neovascularization (CNV). Criterion will be confirmed at Baseline

  2. History of laser therapy in the macular region, regardless of indication

  3. History of herpes zoster

  4. Ophthalmic disease or condition that requires or is likely to require surgery during the study period

  5. GA with cumulative area <1.25 mm2

  6. Any GA lesion within 100 µm radius from the center point of the fovea

  7. Axial length >26 mm

  8. Any ocular disease or condition other than non-neovascular AMD that may, in the opinion of the Investigator, interfere with study assessments, patient adherence to the study schedule, or interpretation of study data (e.g., epiretinal membrane, macular hole, glaucomatous optic neuropathy, etc.)

  9. Intraocular surgery (including cataract extraction and crystalline lens replacement) within 3 months before Visit 1a or yttrium aluminum garnet (YAG) surgery within 2 months before Visit 1a, or planned either during the study period

  10. Use of pegcetacoplan or avacincaptad pegol within 6 months before Visit 1a, or planned use during the study period

  11. Use of any prescription or over-the-counter ophthalmic medication within 1 month before Visit 1a or planned use during the study period

  12. Use of rigid contact lenses within 1 month before Visit 1a or planned use during the study period

    Non-study Eye:

  13. BCVA of <5 letters using ETDRS chart (i.e., 20/800 Snellen equivalent)

    Either Eye:

  14. History of uveitis

  15. GA secondary to any condition other than non-neovascular AMD

  16. History of active ocular infection or inflammation within 3 months before Visit 1a or Baseline. Criterion will be confirmed at Baseline

  17. Underwent investigational treatment for AMD within 6 months before Visit 1a

    General Exclusion Criteria:

  18. History of therapeutic radiation to the cranium

  19. Known allergy or hypersensitivity to the investigational medicinal product (IMP) or any of its excipients

  20. History of malignant disease

  21. Use of hydroxychloroquine within 1 month before Visit 1a, or planned use during the study period

  22. Participated or plan to participate in any other IMP study within 1 month before Visit 1a or during the study period

  23. Use of lutein >10 mg per day or zeaxanthin >2 mg per day within 1 month before Visit 1a, or planned use during the study period

  24. Any medical condition (including mental), in the opinion of the Investigator, that could interfere with study assessments, patient adherence to the study schedule, or interpretation of study data

  25. Screening laboratory values, in the opinion of the Investigator, that make the patient unsuitable for study participation

  26. Pregnant, nursing, or planning a pregnancy during the study. Criterion will be confirmed at Baseline

  27. Unwilling or unable to use an acceptable method of contraception throughout the study if a woman of childbearing potential (WOCBP) or if a sexual partner of a WOCBP

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Firedobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: GAL-101 ophthalmic solution

Patient will apply daily 2 eye drops of GAL-101 at 5 minutes interval

Patient will apply daily 2 eye drops of GAL-101 at 5 minutes interval

Placebo komparator: Placebo

Patient will apply daily 2 eye drops ofPlacebo at 5 minutes interval

Patient will apply daily 2 eye drops of Placebo at 5 minutes interval

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Efficacy of GAL-101 ophthalmic solution in reducing the rate of change in GA lesion size.
Tidsramme: From baseline to last on-treatment visit (48 up to 96 weeks)

Comparison between groups of annual rate of change in the area of GA as measured by fundus autofluorescence (FAF).

From baseline to last on-treatment visit (48 up to 96 weeks)

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Efficacy of GAL-101 ophthalmic solution in reducing the rate of change in photoreceptor degeneration (PRD) in eyes with GA
Tidsramme: From baseline to last on-treatment visit (48 up to 96 weeks)

Comparison between groups of annual rate of change in the area of PRD as measured by optical coherence tomography (OCT)

From baseline to last on-treatment visit (48 up to 96 weeks)

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

10. januar 2025

Primær færdiggørelse (Anslået)

30. marts 2028

Studieafslutning (Anslået)

30. maj 2028

Datoer for studieregistrering

Først indsendt

23. oktober 2024

Først indsendt, der opfyldte QC-kriterier

24. oktober 2024

Først opslået (Faktiske)

26. oktober 2024

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

10. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

9. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

UBESLUTET

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner